Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ovulation suppression refers to the pharmacological or physiological inhibition of ovulation, primarily achieved by suppressing the secretion of gonadotropins (LH and FSH) from the anterior pituitary gland. This is a key mechanism in hormonal contraception, medical therapy for PCOS, and assisted reproductive technologies. Suppression may be accomplished with estrogens, progestins, GnRH agonists, or GnRH antagonists, each acting via distinct effects on the hypothalamic-pituitary-ovarian axis. Drugs that suppress ovulation may act by directly inhibiting LH and FSH secretion, preventing follicle maturation, or blocking the mid-cycle LH surge required for ovulation[2][3]
Inhibition of gonadotropin secretion from the pituitary (LH and FSH), inhibition of follicular development, disruption of LH surge, maintenance of hormone levels that prevent ovulatory signals[2][3]
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ovulation suppression.